Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665372 | 1.00 | POLB (0.59) | POLBALDH1A1SMN1; SMN2TDP1APEX1 | |
| SCHEMBL3777075 | 1.00 | POLB (0.59) | POLBALDH1A1SMN1; SMN2TDP1APEX1 | |
| SCHEMBL3787744 | 1.00 | POLB (0.59) | POLBALDH1A1SMN1; SMN2TDP1APEX1 | |
| SCHEMBL27495 | 1.00 | POLB (0.59) | POLBALDH1A1SMN1; SMN2TDP1APEX1 | |
| SCHEMBL721693 | 0.87 | POLB (0.74) | POLBALDH1A1SMN1; SMN2TDP1APEX1 | |
| Alanine SCHEMBL15656219 | 0.86 | POLB (0.48) | POLBALDH1A1SMN1; SMN2TDP1APEX1 | |
| SCHEMBL23287488 | 0.86 | POLB (0.70) | POLBALDH1A1SMN1; SMN2TDP1APEX1 | |
| SCHEMBL381246 | 0.86 | POLB (0.70) | POLBALDH1A1SMN1; SMN2TDP1APEX1 | |
| SCHEMBL713506 | 0.86 | POLB (0.70) | POLBALDH1A1SMN1; SMN2TDP1APEX1 | |
| SCHEMBL24062391 | 0.86 | POLB (0.70) | POLBALDH1A1SMN1; SMN2TDP1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399897-B1 | METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND | UNIV UTSUNOMIYA (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-8716501-B2 | Method for producing oxygen-containing compound | UTSUNOMIYA UNIVERSITY (JP) | 2014-05-06 | — | — | US | disclosed |
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2013-11-14 | — | — | US | disclosed |
| EP-2601187-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | Conrig Pharma ApS (DK) | 2013-06-12 | — | — | EP | disclosed |
| US-20120053354-A1 | Method for Producing Oxygen-Containing Compound | UTSUNOMIYA UNIVERSITY (JP) | 2012-03-01 | — | — | US | disclosed |
| WO-2012016569-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2012-02-09 | — | — | WO | disclosed |
| EP-2399897-A1 | METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND | Utsunomiya University (JP) | 2011-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | HTR1A, HTR1D, HTR5A | POLB 3260/4885ALDH1A1 620/4885SMN1; SMN2 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.